MTOR and Parkinson disease: Furthermore, RTB101, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), has been tested in a randomized, double-blind, placebo-controlled phase 1b/2a trial of RTB101 alone and in combination with Sirolimus (another inhibitor of mTOR often used an immunosuppressive agent) to be used in PD patients with or without GBA variants (ANZCTR ID: ACTR N12619000372189).